Duration of anticoagulant therapy for venous thromboembolism

Medical Journal of Australia

Volumn 190, Issue 12, 2009, Pages 659-660

  Raju, Nina C ^a   Hirsh, Jack ^a   Eikelboom, John W ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b McMaster Clinic   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN ETEXILATE; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; FACTOR IIA; PROTHROMBIN;

ANTICOAGULANT THERAPY; BLEEDING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; EDITORIAL; HUMAN; LUNG EMBOLISM; POSTTHROMBOSIS SYNDROME; RECURRENCE RISK; TREATMENT DURATION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; BLOOD; DOSE RESPONSE; DRUG EFFECT; METABOLISM; RECURRENT DISEASE; TIME; TREATMENT OUTCOME;

ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; HUMANS; PROTHROMBIN; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 68349083552     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02629.x     Document Type: Editorial

References (14)

1. Ho WK, Hankey GJ, Eikelboom JW. The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. Med J Aust 2008; 189: 144-147.
2. Ho WK, Hankey GJ, Lee CH, Eikelboom JW. Venous thromboembolism: diagnosis and management of deep venous thrombosis. Med J Aust 2005; 182: 476-481. (Pubitemid 40667817)
3. Lee CH, Hankey GJ, Ho WK, Eikelboom JW. Venous thromboembolism: diagnosis and management of pulmonary embolism. Med J Aust 2005; 182: 569-574. (Pubitemid 40823475)
4. Kearon C, Ginsberg JS, Anderson DR, et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2004; 2: 743-749. (Pubitemid 40192487)
5. Pinede L, Ninet J, Duhaut P, et al; Investigators of the Durée Optimale du Treatment AntiVitamines K (DOTAVK) Study. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103: 2453-2460.
6. Campbell IA, Bentley DP, Prescott RJ, et al. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 2007; 334: 674.
7. Pinede L, Duhaut P, Cucherat M, et al. Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials. J Intern Med 2000; 247: 553-562. (Pubitemid 30318058)
8. Ost D, Tepper J, Mihara H, et al. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA 2005; 294: 706-715. (Pubitemid 41159290)
9. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulation therapy for idiopathic deep vein thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001; 345: 165-169.
10. Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 2006; (1): CD001367.
11. Linkins LA, Choi PT, Douketis J. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. Ann Intern Med 2003; 139: 893-900.
12. Kearon C, Ginsberg JS, Kovacs MJ, et al; Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-639.
13. Verma AK, Brighton TA. The direct factor Xa inhibitor rivaroxaban. Med J Aust 2009; 190: 379-383.
14. Kearon C, Kahn S, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133 (6 Suppl): 454S-545S.